Eltrombopag for thrombocytopenia in low- and intermediate-1 risk MDS

Phase 2, randomised trial of eltrombopag in myelodysplastic syndrome (MDS), sponsored by Qol-one. Primary endpoints: Proportion of patients obtaining complete response (CR) or response (R) during the six-month treatment period (Phase 1), Safety and tolerability parameters (Phase 1) and 2 more. Planned start Feb 2025; status: authorised.